{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:21:09Z","timestamp":1769840469766,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41409-019-0690-2","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T14:04:22Z","timestamp":1569420262000},"page":"452-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-4278","authenticated-orcid":false,"given":"Pierre-Edouard","family":"Debureaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Mamez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Lapusan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francoise","family":"Isnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Adaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Delhommeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Vekhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ollivier","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075\u20134083.","journal-title":"Blood"},{"key":"690_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126:319\u2013327.","journal-title":"Blood"},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/jcm4040665","volume":"4","author":"NR Ramos","year":"2015","unstructured":"Ramos NR, Mo CC, Karp JE, Hourigan CS. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4:665\u2013695.","journal-title":"J Clin Med"},{"key":"690_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/leu.2017.23","volume":"31","author":"M Wattad","year":"2017","unstructured":"Wattad M, Weber D, D\u00f6hner K, Krauter J, Gaidzik VI, Paschka P, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31:1306\u20131313.","journal-title":"Leukemia"},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2991\/chi.d.190218.002","volume":"1","author":"RR Potdar","year":"2019","unstructured":"Potdar RR, Gupta S, Giebel S, Savani BN, Varadi G, Nagler A, et al. Current status and perspectives of irradiation-based conditioning regimens for patients with acute leukemia undergoing hematopoietic stem. Cell Transplant Clin Hematol Int. 2019;1:19\u201327.","journal-title":"Cell Transplant Clin Hematol Int"},{"key":"690_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/leu.2011.13","volume":"25","author":"C Craddock","year":"2011","unstructured":"Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25:808\u2013813.","journal-title":"Leukemia"},{"key":"690_CR8","doi-asserted-by":"publisher","unstructured":"Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J et al. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017; 10. \nhttps:\/\/doi.org\/10.1186\/s13045-017-0498-8\n\n.","DOI":"10.1186\/s13045-017-0498-8"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","volume":"29","author":"RF Schlenk","year":"2017","unstructured":"Schlenk RF, M\u00fcller-Tidow C, Benner A, Kieser M. Relapsed\/refractory acute myeloid leukemia: any progress? Curr Opin Oncol. 2017;29:467\u2013473.","journal-title":"Curr Opin Oncol"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2991\/chi.d.190316.001","volume":"1","author":"J Canaani","year":"2019","unstructured":"Canaani J. Management of AML Beyond \u201c3\u2009+\u20097\u201d in 2019. Clin Hematol Int. 2019;1:10\u201318.","journal-title":"Clin Hematol Int"},{"key":"690_CR11","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854\u20134860.","journal-title":"Blood"},{"key":"690_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u2013996.","journal-title":"Lancet Oncol"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26:5192\u20135197.","journal-title":"J Clin Oncol"},{"key":"690_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"A-L Taksin","year":"2007","unstructured":"Taksin A-L, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21:66\u201371.","journal-title":"Leukemia"},{"key":"690_CR15","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia. 2003;17:2318\u20132357.","journal-title":"Leukemia"},{"key":"690_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12475","volume":"7","author":"P Hirsch","year":"2016","unstructured":"Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, et al. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nat Commun. 2016;7:12475.","journal-title":"Nat Commun"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u2013447.","journal-title":"Blood"},{"key":"690_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u2013912.","journal-title":"Bone Marrow Transplant"},{"key":"690_CR19","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20132919.","journal-title":"Blood"},{"key":"690_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"690_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.leukres.2005.02.005","volume":"29","author":"P Chevallier","year":"2005","unstructured":"Chevallier P, Roland V, Mah\u00e9 B, Juge-Morineau N, Dubruille V, Guillaume T, et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2005;29:1003\u20131007.","journal-title":"Leuk Res"},{"key":"690_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00277-016-2899-0","volume":"96","author":"E Paubelle","year":"2017","unstructured":"Paubelle E, Ducastelle-Lepr\u00eatre S, Labussi\u00e8re-Wallet H, Nicolini FE, Barraco F, Plesa A, et al. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? Ann Hematol. 2017;96:363\u2013371.","journal-title":"Ann Hematol"},{"key":"690_CR24","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.3109\/10428194.2014.986478","volume":"56","author":"SP Chantepie","year":"2015","unstructured":"Chantepie SP, Reboursiere E, Mear J-B, Gac A-C, Salaun V, Benabed K, et al. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2015;56:2326\u20132330.","journal-title":"Leuk Lymphoma"},{"key":"690_CR25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.V88.4.1198.bloodjournal8841198","volume":"88","author":"E Solary","year":"1996","unstructured":"Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 1996;88:1198\u20131205.","journal-title":"Blood"},{"key":"690_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie J-N, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508\u20131516.","journal-title":"Lancet"},{"key":"690_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0145-2126(99)00087-9","volume":"23","author":"C Karanes","year":"1999","unstructured":"Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: Southwest Oncology Group Study. Leuk Res. 1999;23:787\u2013794.","journal-title":"Leuk Res"},{"key":"690_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.leukres.2011.10.027","volume":"36","author":"SM Trifilio","year":"2012","unstructured":"Trifilio SM, Rademaker AW, Newman D, Coyle K, Carlson-Leuer K, Mehta J, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res. 2012;36:394\u2013396.","journal-title":"Leuk Res"},{"key":"690_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1365-2141.2003.04728.x","volume":"124","author":"A Virchis","year":"2004","unstructured":"Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 2004;124:26\u201332.","journal-title":"Br J Haematol"},{"key":"690_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","volume":"127","author":"G Olombel","year":"2016","unstructured":"Olombel G, Guerin E, Guy J, Perrot J-Y, Dumezy F, de Labarthe A, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127:2157\u20132160.","journal-title":"Blood"},{"key":"690_CR31","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang Y-C, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2017;35:2674\u20132682.","journal-title":"J Clin Oncol"},{"issue":"4","key":"690_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood-2017-08-802157","volume":"131","author":"Rosemary E. Gale","year":"2018","unstructured":"Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC\/NCRI trials. Blood. 2018;131:468\u2013471.","journal-title":"Blood"},{"key":"690_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/bmt.2016.302","volume":"52","author":"G Battipaglia","year":"2017","unstructured":"Battipaglia G, Labopin M, Candoni A, Fanin R, Cheikh JE, Blaise D, et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2017;52:592.","journal-title":"Bone Marrow Transplant"},{"key":"690_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u20131199.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0690-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:15:51Z","timestamp":1684617351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0690-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"4 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MM has received lecture honoraria from Pfizer whose product is discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}